Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May function as suppressor of malignant melanoma.
Showing 1 out of 4 products:
Both DNMT1 (show DNMT1 ELISA Kits) and AIM1 show maternal allele-specific methylation and paternal allele-specific transcription.
AIM1, ERGIC1 (show ERGIC1 ELISA Kits), and TPX2 (show TPX2 ELISA Kits) were shown to be highly expressed especially in prostate cancer tissues, and high mRNA expression of ERGIC1 (show ERGIC1 ELISA Kits) and TMED3 associated with AR and ERG (show ERG ELISA Kits) oncogene (show RAB1A ELISA Kits) expression
Methylation status of AIM1 in the prostate cancer specimen may predict for time to recurrence in Gleason 3 + 4 = 7 patients undergoing prostatectomy.
AIM1 promoter hypermethylation was found in higher frequency (P = 0.005) in metastatic melanoma (65%) than in primary melanomas (38%).
the structure of AIM1g1, a single betagamma-crystallin domain from the protein absent in melanoma 1, was determined
Absent in melanoma 1 (AIM1), an unusual member of the superfamily , contains 12 betagamma-crystallin motifs in six domains. Some of these motifs diverge considerably from the canonical motif sequence. AIM1g1, the first betagamma-crystallin domain of AIM1.
tumor-promoting effect of deletion in 6q21, that included genes PRDM1 (show PRDM1 ELISA Kits), ATG5 (show ATG5 ELISA Kits) and AIM1
May function as suppressor of malignant melanoma. It may exert its effects through interactions with the cytoskeleton.
absent in melanoma 1 protein
, beta-gamma crystallin domain containing 1
, beta/gamma crystallin domain-containing protein 1
, suppression of tumorigenicity 4 (malignant melanoma)
, absent in melanoma 1
, absent in melanoma 1b